Vascular Endothelial Growth Factor and Endostatin in Angiogenesis After Acute Ischemic Stroke
NCT ID: NCT02157896
Last Updated: 2020-08-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
30 participants
OBSERVATIONAL
2013-05-31
2014-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
68Ga-BNOTA-PRGD2 PET/CT in Evaluation of Stroke
NCT01656785
Prognosis in Subacute Ischemic Stroke Using Multimodal Imaging
NCT06289036
Endovascular Treatment for Stroke Post 1 Day （24 Hours）
NCT06580730
Endovascular Treatment and RIPC in Acute Ischemic Stroke
NCT04581759
Endothelial Function and Progenitor Cells in Acute Ischemic Stroke
NCT01289795
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Acute ischemic stroke
Patients who suffered from acute ischemic stroke within 12 hours for the first time before entry into the study, and had a score between 6 and 25 on the National Institutes of Health Stroke Scale (NIHSS).
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Admission within 12 hours
* National Institutes of Health Stroke Scale score 6-25
Exclusion Criteria
* Cerebral hemorrhagic infarction
* Epilepsy or epileptic persons
* History of neurological diseases, myocardial infarction, renal and hepatic abnormalities and metabolic diseases
* Contraindications to antiplatelet treatments
* Died within the first week of hospitalization
* Serial blood samples could not be obtained
45 Years
74 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shanghai 6th People's Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hao Chen
Doctor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lixia Xue, M.D., Ph.D.
Role: STUDY_DIRECTOR
Shanghai 6th People's Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Shanghai Sixth People's Hospital
Shanghai, , China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
H1583-660110
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.